Cell Medx Corp (OTCBB: CMXC) is in the news for insider trading. Reading a headline with insider trading generally sends chills, especially if you are the part of the management team of said company. But lets consider for a moment that this could be a buy opportunity, or at least an event worthy of shining the spotlight on a small(ish) bio-tech firm.
Cell Medx Corp (OTCBB: CMXC) is an early stage bio-tech firm focusing on the discovery, development and commercialization of therapeutic products. With treatments for diabetes, Parkinsons Disease and high blood pressure in their wheelhouse, Cell Medx is plugged into three of the most significant medical conditions that affect the population.
The company recently announced it had completed the registration process with the FDA, and that it is conducting ongoing clinical trials for a diabetes therapy. According to their most recent financials, they eliminated over $800k of liabilities from their balance sheet, and they have a strong cash reserve, indicators that they are well positioned for reverse mergers or acquisition by a larger, more established company.
Hot Medical Stocks To Own For 2018: Nuveen Select Tax Free Income Portfolio(NXP)
- [By Eric Volkman]
Income investors might be wary of Qualcomm, as the company loves to spend its money — at times, its dividend payouts and share buybacks have exceeded free cash flow. Compounding that matter, the company should soon close the door on its acquisition of European peer NXP Semiconductor (NYSE:NXP), a deal with an estimated enterprise value of $47 billion.
Hot Medical Stocks To Own For 2018: Radient Technologies (RTI)
- [By Matthew Briar]
There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.
It’s yet another reason for RTI investors to be enthused.
Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.
The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.
Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.
The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.
- [By Matthew Briar]
Although the past several years have been very good ones for the cannabis — marijuana and hemp — industry, it’s still mostly being done in an old, artisan-style fashion. Most companies haven’t figured out a way of scaling up their outputs by improving their operating/production efficiency, even though the market’s growth has merited. Radient Technologies Inc (CVE:RTI) represents that next evolution of the cannabinoid business, introducing a new approach to extracting cannabinoids from cannabis plants that will not only improve yields, but create a superior, purer product.
Canada-based Radient Technologies has developed — and patented – an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along. To fully appreciate why it matters, however, one has look at the approach other ingredients suppliers are utilizing now.
With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated to 50 degrees Celsius (or more), and over the course of several hours, the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.
It works, but it’s hardly ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, a lot of things you don’t want to extract can still be found in the extract, lowering the quality and purity of the ingredient.
Radient Technologies’ microwave assisted processing changes all of this.
Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which
- [By Jim Robertson]
Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:
- [By Matthew Briar]
At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”
It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.
No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”
Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho
- [By James E. Brumley]
Some of the stories about how cannabis has changed lives for the better are nothing less than astounding. Take Illinois resident Darren Miller as an example. In 2015 Miller was diagnosed with lung cancer that was later deemed terminal. Miller underwent chemotherapy, without much hope, but also began using high-THC Indica cannabis oil. Miller is alive today, and arguably shouldn’t be.
Then there’s Floridian Branden Petro. Not only does Petro suffer epilepsy, he commonly experiences seizures stemming from the condition. Nothing has stopped the seizures as quickly or effectively as 200 milligram worth of THC cannabis oil, administered as a nasal spray. Within 20 seconds of using it, it’s as of the seizure never happened.
And there are millions of other such (and less dramatic) examples, all pointing in the same direction – cannabis has medical value on multiple fronts. Not facilitating its commercialization is a wasted opportunity.
It’s a notion that’s far from lost on the people that have built Canadian-based Radient Technologies Inc (CVE:RTI) from the round up, recently inking a deal with supplier of cannabinoid extracts, Aurora Cannabis.
It’s a real accolade. Aurora is one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.
In most regards though, Radient Technologies is the big winner of the deal, as the partnership is apt to put its high-tech facility in full demand, helping to advance the advent of cannabis in all its potential glory.
It’s a rather amazing science, really. Radient Technologies uses an ingredient-extraction process called microwave assisted proc
Hot Medical Stocks To Own For 2018: Federal-Mogul Holdings Corporation(FDML)
- [By Benzinga News Desk]
Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.
Hot Medical Stocks To Own For 2018: BioLineRx Ltd.(BLRX)
- [By William Romov]
Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.
- [By Jim Robertson]
On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:
Hot Medical Stocks To Own For 2018: Brown & Brown, Inc.(BRO)
- [By Ben Levisohn]
BMO also upgraded Arch Capital Group (ACGL), Brown & Brown (BRO), and Travelers (TRV).
Shares of American International Group have declined 0.4% to $65.60 at 3:36 p.m. today, whileArch Capital Group has gained 2% to $87.90,Brown & Brown has advanced 0.5% to $44.65, andTravelers has risen 1.3% to $120.79.
Hot Medical Stocks To Own For 2018: 3D Systems Corporation(DDD)
- [By Peter Graham]
A long term performance chart shows ExOne Co along with other small cap 3D printing stocks like3D Systems Corporation (NYSE: DDD), Stratasys, Ltd (NASDAQ: SSYS) and Voxeljet AG (NYSE: VJET) all peaking in 2013/2014 with the bubble clearly bursting since then:
- [By Jack Delaney]
Here are 10 virtual reality stocks to watch in 2017, with today’s opening price (Feb. 22) and the year-to-date (YTD) return thus far:
3D Systems Corp. (NYSE: DDD); $17.12; +26.71% YTDUniversal Display Corp. (Nasdaq: OLED); $71.60; +25.49% YTDAdvanced Micro Devices Inc. (Nasdaq: AMD); $14.30; +24.22% YTDFacebook Inc. (Nasdaq: FB); $133.60; +18.64% YTDAdobe Systems Inc. (Nasdaq: ADBE); $119.67; +15.93% YTDSony Corp. (NYSE ADR: SNE); $31.29; +11.49% YTDAlphabet Inc. (Nasdaq: GOOGL); $848; +7.49% YTDAmbarella Inc. (Nasdaq: AMBA); $57.85; +6.26% YTDMicrosoft Corp. (Nasdaq: MSFT); $64.33; +3.16% YTDRockwell Collins Inc. (NYSE: COL); $93.97; +0.97% YTD
The virtual reality industry could reach $33.9 billion in value by 2022, which is why virtual reality stocks are more popular than ever.
- [By Beth McKenna]
While Stratasys’ stock is still down significantly from its all-time high, it’s showing signs of life this year. It’s gained 17% in 2017, through March 3, outpacing rival 3D Systems’ (NYSE:DDD)9.3% gain and the S&P 500’s total return of 6.9%. Shares of 3D Systems had been riding higher in 2017, through plummeted 10% after the company announced earnings on Feb. 28. Quarterly revenue and 2017 revenue guidance came in lighter than Wall Street analysts were expecting.